- Home
- SKYE vs QUIK Comparison
SKYE vs QUIK Comparison
Compare SKYE & QUIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- QUIK
- Stock Information
- Founded
- SKYE 2012
- QUIK 1988
- Country
- SKYE United States
- QUIK United States
- Employees
- SKYE N/A
- QUIK N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- QUIK Semiconductors
- Sector
- SKYE Health Care
- QUIK Technology
- Exchange
- SKYE Nasdaq
- QUIK Nasdaq
- Market Cap
- SKYE 80.7M
- QUIK 87.3M
- IPO Year
- SKYE N/A
- QUIK 1997
- Fundamental
- Price
- SKYE $1.81
- QUIK $5.90
- Analyst Decision
- SKYE Buy
- QUIK Strong Buy
- Analyst Count
- SKYE 6
- QUIK 3
- Target Price
- SKYE $16.60
- QUIK $11.53
- AVG Volume (30 Days)
- SKYE 1.7M
- QUIK 94.9K
- Earning Date
- SKYE 05-08-2025
- QUIK 05-13-2025
- Dividend Yield
- SKYE N/A
- QUIK N/A
- EPS Growth
- SKYE N/A
- QUIK N/A
- EPS
- SKYE N/A
- QUIK N/A
- Revenue
- SKYE N/A
- QUIK $20,112,000.00
- Revenue This Year
- SKYE N/A
- QUIK $22.56
- Revenue Next Year
- SKYE N/A
- QUIK $21.66
- P/E Ratio
- SKYE N/A
- QUIK N/A
- Revenue Growth
- SKYE N/A
- QUIK N/A
- 52 Week Low
- SKYE $1.14
- QUIK $4.26
- 52 Week High
- SKYE $13.49
- QUIK $16.13
- Technical
- Relative Strength Index (RSI)
- SKYE 48.48
- QUIK 59.62
- Support Level
- SKYE $1.36
- QUIK $5.31
- Resistance Level
- SKYE $2.30
- QUIK $5.98
- Average True Range (ATR)
- SKYE 0.21
- QUIK 0.35
- MACD
- SKYE 0.02
- QUIK 0.12
- Stochastic Oscillator
- SKYE 42.35
- QUIK 83.53
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.